Abstract
Molecular biological characterization of tumors has become a pivotal procedure for glioma patient care. The aim of this study is to build conventional MRI-based radiomics model to predict genetic alterations within grade II/III gliomas attempting to implement lesion location information in the model to improve diagnostic accuracy. One-hundred and ninety-nine grade II/III gliomas patients were enrolled. Three molecular subtypes were identified: IDH1/2-mutant, IDH1/2-mutant with TERT promoter mutation, and IDH-wild type. A total of 109 radiomics features from 169 MRI datasets and location information from 199 datasets were extracted. Prediction modeling for genetic alteration was trained via LASSO regression for 111 datasets and validated by the remaining 58 datasets. IDH mutation was detected with an accuracy of 0.82 for the training set and 0.83 for the validation set without lesion location information. Diagnostic accuracy improved to 0.85 for the training set and 0.87 for the validation set when lesion location information was implemented. Diagnostic accuracy for predicting 3 molecular subtypes of grade II/III gliomas was 0.74 for the training set and 0.56 for the validation set with lesion location information implemented. Conventional MRI-based radiomics is one of the most promising strategies that may lead to a non-invasive diagnostic technique for molecular characterization of grade II/III gliomas.
Highlights
IntroductionIdentifying IDH1/2 mutation and 1p/19q chromosomal codeletion is essential for the final pathological diagnosis of either an astrocytic or oligodendroglial tumor[1,2,3,4]
The authors further pursuit the possibility of implementing lesion locations into magnetic resonance imaging (MRI) radiomics and devised a method for non-invasive molecular biological diagnosis of World Health Organization (WHO) grade II and III gliomas using conventional MRI alone
IDH1/2 and TERT promoter mutations were used for molecular subtype classification
Summary
Identifying IDH1/2 mutation and 1p/19q chromosomal codeletion is essential for the final pathological diagnosis of either an astrocytic or oligodendroglial tumor[1,2,3,4] These molecular markers can be further utilized for predicting sensitivity of the tumor to chemotherapy and radiation and for further prognostication of the patient[3,4]. The authors further pursuit the possibility of implementing lesion locations into magnetic resonance imaging (MRI) radiomics and devised a method for non-invasive molecular biological diagnosis of World Health Organization (WHO) grade II and III gliomas (grade II/III gliomas) using conventional MRI alone
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call